Practice points
_ Sero-negative RA signifies an important disease burden, for which
prompt therapeutic
intervention remains to be vulnerable to diagnostic challenges.
_ Currently, there is inadequate evidence to support a modified
treatment strategy for the
seronegative RA, even though the value of initial combination DMARD use,
and that of B-cell depletion therapy, may be less than in seropositive
disease.